JPH0459315B2 - - Google Patents
Info
- Publication number
- JPH0459315B2 JPH0459315B2 JP10013385A JP10013385A JPH0459315B2 JP H0459315 B2 JPH0459315 B2 JP H0459315B2 JP 10013385 A JP10013385 A JP 10013385A JP 10013385 A JP10013385 A JP 10013385A JP H0459315 B2 JPH0459315 B2 JP H0459315B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- solvent
- reaction
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(産業上の利用分野)
本発明は新規な1,3−ジチオール化合物に関
する。
(従来の技術)
一般式
で表わされる1,3−ジチオール化合物におい
て、R′が低級アルキル基である1,3−ジチオ
ール化合物は、例えば特公昭49−35272、特開昭
51−144734及び特開昭52−83751等に記載された
公知化合物であり、肝疾患用剤として有効である
ことが報告されているが、その問題点として胃腸
障害が現われることが指摘されている。
(発明が解決しようとする問題点)
本発明の目的はより優れた肝疾患治療効果を有
し、更に副作用の胃腸障害が軽減された新規な
1,3−ジチオール化合物を提供することにあ
る。
(問題点を解決するための手段)
本発明は一般式
(式中Rは
(Industrial Application Field) The present invention relates to a novel 1,3-dithiol compound. (Prior art) General formula In the 1,3-dithiol compound represented by, R' is a lower alkyl group, for example, the 1,3-dithiol compound represented by
It is a known compound described in JP-A-51-144734 and JP-A-52-83751, etc., and is reported to be effective as a drug for liver diseases, but it has been pointed out that its problem is that it causes gastrointestinal disorders. . (Problems to be Solved by the Invention) An object of the present invention is to provide a novel 1,3-dithiol compound that has a better therapeutic effect on liver diseases and has reduced side effects of gastrointestinal disorders. (Means for solving the problems) The present invention is based on the general formula (In the formula, R is
【式】【formula】
【式】【formula】
【式】【formula】
【式】【formula】
【式】 又は【formula】 or
【式】
を示す)で表わされる1,3−ジチオール化合物
に係る。
本発明の上記一般式(1)で示される1,3−ジチ
オール化合物は文献未載の新規化合物であり、肝
機能改善作用を有し肝疾患治療剤として有用であ
る。
本発明の一般式(1)で示される1,3−ジチオー
ル化合物は、例えば以下の方法により製造され
る。溶媒中、水素化カルシウム、リチウムジイソ
プロピルアミン、水素化ナトリウム等の塩基の存
在下、一般式(2)で示される化合物に、2−メチル
チオ−1,3−ジチオリウムアイオダイド(3)を作
用させる方法で、次の反応式で表わされる。
(式中Rは前記と同じ)
反応に使用される溶剤としては、例えばジオキ
サン、テトラハイドロフラン(THF)、1,2−
ジメトキシエタン等のエーテル類が好適に使用さ
れる。また化合物(2)と(3)の使用割合は等量使用す
るのが有利である。反応温度も適宜選択すればよ
いが一般に0℃〜室温程度で行うのが有利であ
る。
尚、本反応において出発原料として用いられる
化合物(2)は文献未載の新規化合物であり、例えば
マロン酸ジクロライド(4)より以下に示す工程によ
つて製造される。
(式中Rは前記と同じ)
即ち化合物(4)に塩基の存在下、アルコール(5)を
作用させることにより化合物(2)が得られる。
上記方法により得られた本発明化合物(1)の単離
精製は、例えば抽出、再結晶、カラムクロマトグ
ラフイー等の通常の操作によつて行なわれる。
(実施例)
以下本発明の1,3−ジチオール化合物の合成
例を実施例として、さらに出発原料化合物の合成
例を参考例として次に説明する。
参考例 1
1,3−ジオキソラン−4−メタノール3.12g
を乾燥ジクロルメタン50mlに溶解しトリエチルア
ミン4.60mlを加える。氷冷下、マロン酸ジクロラ
イド1.60mlを乾燥ジクロルメタン2.0mlに溶解し
た溶液を滴下する。室温で3時間撹拌を行い、反
応後氷水に注ぎ、有機層は分取し無水硫酸マグネ
シウムで乾燥する。乾燥後、溶媒を留去し残渣は
カラムクロマトグラフイー(展開溶媒;クロロホ
ルム:アセトン=5:1)にて分離精製し油状物
〔化合物A〕2.77g(67%)を得る。尚、 1H−
NMR(プロトン核磁気気共鳴)による分析結果
を第1表に示す。
参考例 2
N−メチルピペリジン−3−メタノール3.0g
を乾燥ジクロルメタン50mlに溶解し、氷冷下マロ
ン酸ジクロライド1.24mlを乾燥ジクロルメタン8
mlに溶解した溶液を滴下する。室温で20時間攪拌
した後、反応液に5規定の水酸化ナトリウム水溶
液を加え、酢酸エチルにて抽出した。抽出液を水
洗後、乾燥した後、溶媒留去する。残渣〔化合物
B〕は精製せず、次の反応に用いた。尚、 1H−
NMRによる分析結果を第1表に示す。
参考例 3〜7
参考例2と同様の操作により化合物C,D,
G,H,Iを合成した。尚、 1H−NMRによる
分析結果を第1表に示す。
参考例 8
1−ピペラジンエタノール10gとα−ブロモア
セトフエノン15.5gをジクロルメタン70ml中で室
温下18時間攪拌する。析出物はロ取した後、結晶
は3規定の水酸化ナトリウム溶液に加え、クロロ
ホルムにて抽出する。抽出液を乾燥後、溶媒留去
し4−ベンゾイルメチル−1−ピペラジンエタノ
ールの結晶15g(79%)を得る。
4−ベンゾイルメチル−1−ピペラジンエタノ
ール5gを乾燥ジクロルメタン100mlに溶解し、
氷冷下マロニルジクロライド1.5gを滴下する。
同温度で2時間攪拌の後、2規定の水酸化ナトリ
ウム溶液を加え、ジクロルメタン層は分取し、こ
の分取した層を水洗後、乾燥した後、溶媒を留去
し、残渣はカラムクロマトグラフイー(展開溶
媒;クロロホルム:エタノール=8:1)にて分
離精製し油状物〔化合物E〕3.0g(27%)を得
る。尚、 1H−NMRによる分析結果を第1表に
示す。
参考例 9
1−ベンジルオキシカルボニル−ピロリジン−
2−カルボン酸24gをジメチルホルムアミド120
mlに溶解し、カルボニルジイミダゾール15.6gを
加え40℃で1時間攪拌する。次にtert.−ブタノー
ル14.4gと1,8−ジアザビシクロ〔5,4,
0〕−7−ウンデセン(DBU)14.6gを加え、室
温にて24時間攪拌する。反応液をエーテルにて抽
出する。抽出液は1規定の塩酸、次いで水で洗浄
後、乾燥した後、溶媒を留去し、tert.−ブチル1
−ベンジルオキシカルボニル−ピロリジン−2−
カルボキシレート26g(88%)を得る。
tert.−ブチル1−ベンジルオキシカルボニル−
ピロリジン−2−カルボキシレート15gをメタノ
ール150mlに溶解し、10%パラジウム−炭素3g
を加え常圧で水素添加する。反応液をロ過し、ロ
液は濃縮し、tert.−ブチル ピロリジン−2−カ
ルボキシレート6.5g(77%)を得る。
tert.−ブチル ピロリジン−2−カルボキシレ
ート3.3gをエタノール50mlに溶解し、氷冷下プ
ロピレンオキサイド1.3gを滴下する。滴下後、
室温にて2日間攪拌する。反応後、濃縮し、ベン
ゼンを加え抽出する。抽出液は水洗後、乾燥した
後、溶媒を留去し、tert.−ブチル 1−(2−ヒ
ドロキシプロピル)ピロリジン−2−カルボキシ
レート3.7g(84%)を得る。
tert.−ブチル 1−(2−ヒドロキシプロピル)
ピロリジン−2−カルボキシレート3.7gをジク
ロルメタン40ml溶解し、氷冷下マロニルジクロラ
イド1.4gを滴下する。滴下後、室温で4時間攪
拌する。反応後、1規定水酸化ナトリウム溶液を
加え振とうし、ジクロルメタン層は分取し、乾燥
した後、溶媒を留去する。残渣をカラムクロマト
グラフイー(展開溶媒;クロロホルム:アセトン
=7:1)で分離精製し油状物〔化合物F〕2.1
g(25%)を得る。尚、 1H−NMRによる分析
結果を第1表に示す。The present invention relates to a 1,3-dithiol compound represented by the following formula. The 1,3-dithiol compound of the present invention represented by the above general formula (1) is a novel compound that has not been described in any literature, and has a liver function improving effect and is useful as a therapeutic agent for liver diseases. The 1,3-dithiol compound represented by the general formula (1) of the present invention is produced, for example, by the following method. 2-methylthio-1,3-dithiolium iodide (3) is allowed to act on the compound represented by general formula (2) in a solvent in the presence of a base such as calcium hydride, lithium diisopropylamine, or sodium hydride. This method is expressed by the following reaction formula. (In the formula, R is the same as above.) Examples of the solvent used in the reaction include dioxane, tetrahydrofuran (THF), 1,2-
Ethers such as dimethoxyethane are preferably used. Furthermore, it is advantageous to use equal amounts of compounds (2) and (3). Although the reaction temperature may be selected appropriately, it is generally advantageous to carry out the reaction at a temperature of about 0°C to room temperature. The compound (2) used as a starting material in this reaction is a new compound that has not been described in any literature, and is produced, for example, from malonic acid dichloride (4) by the steps shown below. (In the formula, R is the same as above.) That is, compound (2) is obtained by reacting alcohol (5) with compound (4) in the presence of a base. Isolation and purification of the compound (1) of the present invention obtained by the above method is carried out by conventional operations such as extraction, recrystallization, column chromatography, and the like. (Example) Synthesis examples of the 1,3-dithiol compound of the present invention will be described below as examples, and further synthesis examples of starting material compounds will be described as reference examples. Reference example 1 1,3-dioxolane-4-methanol 3.12g
Dissolve in 50 ml of dry dichloromethane and add 4.60 ml of triethylamine. Under ice cooling, a solution of 1.60 ml of malonic acid dichloride dissolved in 2.0 ml of dry dichloromethane is added dropwise. Stirring is carried out at room temperature for 3 hours, and after the reaction, the mixture is poured into ice water, and the organic layer is separated and dried over anhydrous magnesium sulfate. After drying, the solvent was distilled off and the residue was separated and purified by column chromatography (developing solvent: chloroform:acetone=5:1) to obtain 2.77 g (67%) of an oil [Compound A]. Furthermore, 1 H−
Table 1 shows the analysis results by NMR (proton nuclear magnetic resonance). Reference example 2 N-methylpiperidine-3-methanol 3.0g
was dissolved in 50 ml of dry dichloromethane, and 1.24 ml of malonic acid dichloride was dissolved in 8 ml of dry dichloromethane under ice-cooling.
Drop the solution dissolved in ml. After stirring at room temperature for 20 hours, a 5N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. After washing the extract with water and drying, the solvent is distilled off. The residue [Compound B] was used in the next reaction without being purified. Furthermore, 1 H−
Table 1 shows the results of NMR analysis. Reference Examples 3 to 7 Compounds C, D,
G, H, and I were synthesized. Incidentally, the analysis results by 1 H-NMR are shown in Table 1. Reference Example 8 10 g of 1-piperazine ethanol and 15.5 g of α-bromoacetophenone were stirred in 70 ml of dichloromethane at room temperature for 18 hours. After the precipitate is filtered off, the crystals are added to 3N sodium hydroxide solution and extracted with chloroform. After drying the extract, the solvent was distilled off to obtain 15 g (79%) of crystals of 4-benzoylmethyl-1-piperazineethanol. Dissolve 5 g of 4-benzoylmethyl-1-piperazine ethanol in 100 ml of dry dichloromethane,
Add 1.5 g of malonyl dichloride dropwise while cooling on ice.
After stirring at the same temperature for 2 hours, 2N sodium hydroxide solution was added, the dichloromethane layer was separated, the separated layer was washed with water, dried, the solvent was distilled off, and the residue was subjected to column chromatography. Separation and purification using E (developing solvent; chloroform:ethanol = 8:1) yielded 3.0 g (27%) of an oil [Compound E]. Incidentally, the analysis results by 1 H-NMR are shown in Table 1. Reference example 9 1-benzyloxycarbonyl-pyrrolidine-
24 g of 2-carboxylic acid to 120 g of dimethylformamide
ml, add 15.6 g of carbonyldiimidazole, and stir at 40°C for 1 hour. Next, 14.4 g of tert.-butanol and 1,8-diazabicyclo[5,4,
0]-7-Undecene (DBU) (14.6 g) was added, and the mixture was stirred at room temperature for 24 hours. The reaction solution was extracted with ether. The extract was washed with 1N hydrochloric acid and then with water, dried, the solvent was distilled off, and tert.-butyl 1
-benzyloxycarbonyl-pyrrolidine-2-
26 g (88%) of carboxylate are obtained. tert.-butyl 1-benzyloxycarbonyl-
Dissolve 15 g of pyrrolidine-2-carboxylate in 150 ml of methanol, and dissolve 3 g of 10% palladium-carbon.
and hydrogenate at normal pressure. The reaction solution was filtered and the filtrate was concentrated to obtain 6.5 g (77%) of tert.-butyl pyrrolidine-2-carboxylate. 3.3 g of tert.-butyl pyrrolidine-2-carboxylate is dissolved in 50 ml of ethanol, and 1.3 g of propylene oxide is added dropwise under ice cooling. After dripping,
Stir for 2 days at room temperature. After the reaction, it is concentrated and extracted with benzene. After washing the extract with water and drying, the solvent was distilled off to obtain 3.7 g (84%) of tert.-butyl 1-(2-hydroxypropyl)pyrrolidine-2-carboxylate. tert.-butyl 1-(2-hydroxypropyl)
3.7 g of pyrrolidine-2-carboxylate was dissolved in 40 ml of dichloromethane, and 1.4 g of malonyl dichloride was added dropwise under ice cooling. After the addition, the mixture was stirred at room temperature for 4 hours. After the reaction, 1N sodium hydroxide solution is added and shaken, the dichloromethane layer is separated, dried, and the solvent is distilled off. The residue was separated and purified by column chromatography (developing solvent: chloroform:acetone = 7:1) to obtain an oil [Compound F] 2.1
g (25%). Incidentally, the analysis results by 1 H-NMR are shown in Table 1.
【表】【table】
【表】
実施例 1
乾燥THF(12ml)に60%水素化ナトリウム0.4
gを加え、氷冷下、ビス〔(1,3−ジオキソデ
ン−4−イル)−メチル〕〔化合物A〕2.77gを滴
下する。次に室温で1時間攪拌を行い、再び氷冷
し2−メチルチオ−1,3−ジチオリウムアイオ
ダイド2.77gを加え、室温で3時間攪拌する。反
応液に水を加え酢酸エチル60mlで2回抽出する。
無水硫酸マグネシウムで乾燥した後、溶媒を留去
し、残渣をエーテルより結晶化する。粗結晶をロ
取し、酢酸エチルより再結晶し、mp110〜112℃
の結晶〔化合物1〕0.6g(16%)を得た。
実施例2〜5及び実施例7〜9
実施例1と同様の操作により、化合物B〜E、
G〜Iを原料として化合物2〜5及び7〜9を合
成した。尚、化合物2〜5及び7〜8はマレイン
酸塩として、化合物9は塩酸塩として精製した。
実施例 6
乾燥THF(50ml)に50%水素化ナトリウム0.2
gを加え、氷冷下、化合物F(2.1g)を徐々に加
える。次に室温で2時間攪拌後、再び氷冷し、2
−メチルチオ−1,3−ジチオリウムアイオダイ
ド1.2gを加え、室温で3時間攪拌する。反応後、
溶媒を留去し残渣はCHCl3(50ml)で2回抽出し、
無水硫酸マグネシウムで乾燥した後、溶媒を留去
する。残渣をシリカゲルカラムクロマトグラフイ
ー(展開溶媒;クロロホルム:アセトン=10:
1)にて精製し油状物のビス〔(2−tert−ブト
キシカルボニル−ピロリジン−1−イル)−2−
プロピル〕1,3−ジチオール−2−イリデンマ
ロネート1.5g(60%)を得た。
上記化合物0.2gにトリフルオロ酢酸2mlを加
え、室温にて18時間攪拌する。反応後、溶媒を留
去し残渣は重ソウ水でPH8〜9に調節しMCIゲ
ル(三菱化成製)にて分離精製した。溶出液は凍
結乾燥して、mp131〜133℃の化合物6を0.1g
(56%)得た。化合物1〜9の 1H−NMR、元素
分析値を第2表に示す。第2表の 1H−NMRに
おいて(イ)はCDCl3、(ロ)はDMSO−d6、(ハ)はD2Oを
溶媒としたことを示す。また元素分析において(C)
は計算値、(F)は分析値を示す。[Table] Example 1 60% sodium hydride 0.4 in dry THF (12 ml)
g, and 2.77 g of bis[(1,3-dioxoden-4-yl)-methyl][Compound A] was added dropwise under ice cooling. Next, the mixture was stirred at room temperature for 1 hour, cooled on ice again, 2.77 g of 2-methylthio-1,3-dithiolium iodide was added, and the mixture was stirred at room temperature for 3 hours. Add water to the reaction solution and extract twice with 60 ml of ethyl acetate.
After drying over anhydrous magnesium sulfate, the solvent is distilled off and the residue is crystallized from ether. The crude crystals were collected by filtration and recrystallized from ethyl acetate, mp110-112℃.
0.6 g (16%) of crystals [Compound 1] were obtained. Examples 2 to 5 and Examples 7 to 9 Compounds B to E,
Compounds 2 to 5 and 7 to 9 were synthesized using G to I as raw materials. Note that Compounds 2 to 5 and 7 to 8 were purified as maleate salts, and Compound 9 was purified as hydrochloride. Example 6 0.2 50% sodium hydride in dry THF (50 ml)
g, and then slowly add compound F (2.1 g) under ice cooling. Next, after stirring at room temperature for 2 hours, cooling on ice again,
Add 1.2 g of -methylthio-1,3-dithiolium iodide and stir at room temperature for 3 hours. After the reaction,
The solvent was distilled off and the residue was extracted twice with CHCl 3 (50 ml).
After drying over anhydrous magnesium sulfate, the solvent is distilled off. The residue was subjected to silica gel column chromatography (developing solvent: chloroform:acetone = 10:
1) to obtain an oily bis[(2-tert-butoxycarbonyl-pyrrolidin-1-yl)-2-
1.5 g (60%) of propyl]1,3-dithiol-2-ylidene malonate was obtained. Add 2 ml of trifluoroacetic acid to 0.2 g of the above compound and stir at room temperature for 18 hours. After the reaction, the solvent was distilled off, and the residue was adjusted to pH 8 to 9 with sodium hydrogen aqueous solution, and separated and purified using MCI gel (manufactured by Mitsubishi Kasei). The eluate was lyophilized and 0.1g of compound 6 with mp131-133℃
(56%) obtained. 1 H-NMR and elemental analysis values of Compounds 1 to 9 are shown in Table 2. In 1 H-NMR in Table 2, (a) indicates that CDCl3 , (b) DMSO- d6 , and (c) D2O were used as solvents. Also, in elemental analysis (C)
indicates the calculated value, and (F) indicates the analytical value.
【表】【table】
【表】【table】
Claims (1)
物。[Claims] 1. General formula (In the formula, R is [formula] [formula] [formula] [formula] A 1,3-dithiol compound represented by [Formula] [Formula] [Formula] or [Formula].
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10013385A JPS61263975A (en) | 1985-05-10 | 1985-05-10 | 1,3-dithiol compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10013385A JPS61263975A (en) | 1985-05-10 | 1985-05-10 | 1,3-dithiol compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61263975A JPS61263975A (en) | 1986-11-21 |
| JPH0459315B2 true JPH0459315B2 (en) | 1992-09-21 |
Family
ID=14265813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10013385A Granted JPS61263975A (en) | 1985-05-10 | 1985-05-10 | 1,3-dithiol compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61263975A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960000743B1 (en) * | 1988-01-26 | 1996-01-12 | 다이아호일 가부시끼가이샤 | Laminated polyester film |
-
1985
- 1985-05-10 JP JP10013385A patent/JPS61263975A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61263975A (en) | 1986-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514381A5 (en) | ||
| JPH04134077A (en) | Isoxazole compound | |
| JP3173602B2 (en) | Novel intermediate for the production of enyne derivatives and its production method | |
| EP0406112B1 (en) | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | |
| JPH01149764A (en) | Bis-s-alkylbenzene derivative | |
| JPS626718B2 (en) | ||
| US6271371B1 (en) | Oxidative process and products thereof | |
| CN103739541B (en) | The preparation method of 5,6-dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-piperidino) phenyl]-2 (1H)-pyridones | |
| JP3207017B2 (en) | Method for producing benzylsuccinic acid derivative and intermediate for producing the same | |
| JP2578797B2 (en) | Method for producing N- (sulfonylmethyl) formamides | |
| JPS6355512B2 (en) | ||
| WO1999031097A1 (en) | Imidazol derivatives as muscarinic m3 receptor antagonists | |
| JPS61263975A (en) | 1,3-dithiol compound | |
| CN110590641B (en) | A kind of green preparation method of 3-hydroxyisoindol-1-one series compounds | |
| JP3489689B2 (en) | Method for producing 1-arylpyrazolidine-3-thione derivative | |
| JP2905931B2 (en) | Process for producing optically active 2-cyclopentenones | |
| JP2671401B2 (en) | .ALPHA.-Aminothioacetamide derivative and its production method | |
| JPH0522712B2 (en) | ||
| JPS6241510B2 (en) | ||
| KR800001450B1 (en) | Method for preparing 1, 3, 5-trisubstituted benzene derivative | |
| JPH027583B2 (en) | ||
| JPH01168664A (en) | Cyclohexenone derivative and production thereof | |
| FR2511677A1 (en) | PROCESS FOR THE PREPARATION OF ESTERS OF ALCOXYVINCAMINIC ACIDS AND ALCOXYAPOVINCAMINE | |
| JP3495774B2 (en) | Method for producing 1-hydroxyindoles | |
| JP2782755B2 (en) | Method for producing 3a, 8b-cis-dihydro-3H-5,7-dibromocyclopenta [b] benzofuran |